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T-cell therapy after hematopoietic stem cell transplantation (HSCT) has been used alone or
in combination with immunosuppression to cure hematologic malignancies and to prevent
disease recurrence. Here, we describe the outcome of patients with high-risk/advanced
stage hematologic malignancies, who received T-cell depleted (TCD) haploidentical-HSCT
(haplo-HSCT) combined with donor T lymphocytes pretreated with IL-10 (ALT-TEN trial).
IL-10-anergized donor T cells (IL-10-DLI) contained T regulatory type 1 (Tr1) cells specific
for the host alloantigens, limiting donor-vs.-host-reactivity, and memory T cells able to
respond to pathogens. IL-10-DLI were infused in 12 patients with the goal of improving
immune reconstitution after haplo-HSCT without increasing the risk of graft-versus-host-
disease (GvHD). IL-10-DLI led to fast immune reconstitution in five patients. In four out of
the five patients, total T-cell counts, TCR-Vβ repertoire and T-cell functions progressively
normalized after IL-10-DLI.These four patients are alive, in complete disease remission and
immunosuppression-free at 7.2 years (median follow-up) after haplo-HSCT.Transient GvHD
was observed in the immune reconstituted (IR) patients, despite persistent host-specific
hypo-responsiveness of donor T cells in vitro and enrichment of cells with Tr1-specific bio-
markers in vivo. Gene-expression profiles of IR patients showed a common signature of
tolerance. This study provides the first indication of the feasibility of Tr1 cell-based therapy
and paves way for the use of these Tr1 cells as adjuvant treatment for malignancies and
immune-mediated disorders.
Keywords: hematopoietic stem cell transplantation, haploidentical, IL-10, T regulatory type 1 cells, cell therapy,
tolerance
INTRODUCTION
The long-term benefit and wide applicability of T-cell-depleted
(TCD) haploidentical-HSC transplantation (haplo-HSCT), have
been limited by slow immune reconstitution and high relapse rate
(1–6). Infusion of unmanipulated donor lymphocyte (DLI) to
improve immune reconstitution and to prevent relapse led to high
incidence of severe graft-versus-host disease (GvHD) (3, 7).
During the last decade, considerable progress has been made on
the use of ex vivo manipulated T cells as a new advanced therapeu-
tics to promote graft-versus-leukemia (GvL) and immune recon-
stitution without GvHD after HSCT (8, 9). For example, chimeric
antigen-receptor modified T cells to directly treat leukemia or
suicide-gene expressing T cells have been successfully employed
(9–12). In addition, freshly isolated or expanded CD4+CD25+
T regulatory (Treg) cells have been used as adjuvant therapy to
suppress GvHD after allogeneic HSCT in patients with hema-
tologic malignancies (13–15). These Treg cell therapies are safe,
although tested in a small number of patients, but their efficacy
is still controversial. In addition, many open questions remain on
the best source of Treg cells to be administered, the optimal cell
dose, the survival and behavior of these cells once they are in the
host environment, and their mechanism of action.
Peripheral T regulatory type 1 (Tr1) cells, with alloantigen
(Allo-Ag)-specific suppressor function, have been consistently
associated to a state of tolerance in chimeric patients after allo-
geneic HSCT. In addition, several preclinical studies demonstrated
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that Tr1 cells play a major role in the induction and maintenance
of transplantation tolerance (16–21). Tr1 cells are characterized
by a unique cytokine production profile (IL-10+IL-4−IL-17−)
(17, 21), and by the co-expression of CD49b and LAG-3 (22).
Tr1 cells control immune responses by secreting high levels of
IL-10, and by killing myeloid cells (17, 23). Allo-Ag-specific Tr1
cells can be induced in vitro in the presence of IL-10 (17, 24, 25).
Activation of T cells by Allo-Ags in the presence of IL-10 induces
Ag-specific hypo-responsiveness, identified as T-cell anergy (26,
27). These IL-10-anergized T cells contain Tr1 cells, as demon-
strated at single-cell level (17), but also memory T cells able to
proliferate in response to nominal Ags, such as tetanus toxoid and
Candida albicans, and viral Ags, such as Epstein-Barr virus (25). In
a murine model of allogeneic HSCT, transfer of IL-10-anergized T
cells prevented GvHD (28). These findings provided the rationale
for the clinical use of IL-10-anergized donor T cells (IL-10-DLI)
to support immune reconstitution without severe GvHD after
allo-HSCT.
We developed a GMP-validated protocol to obtain IL-10-DLI,
from haploidentical hematopoietic stem cell donors (25, 29).
In a small proof-of-concept clinical trial (ALT-TEN trial), 12
patients who received TCD haplo-HSCT were treated with IL-
10-DLI. Here, we describe the positive outcome of TCD haplo-
HSCT combined with IL-10-DLI cell therapy in four patients
with high-risk/advanced stage hematologic malignancies. These
patients achieved full donor chimerism, immune reconstitution,
and long-term persistent disease remission. Cells from all four
patients expressed biomarkers consistent with tolerance and Tr1
cell enrichment. This study indicates the feasibility of cell ther-
apy with IL-10-DLI to promote fast immune reconstitution and
tolerance after haplo-HSCT.
MATERIALS AND METHODS
PATIENTS AND TRANSPLANT PROCEDURES
Nineteen patients with high-risk hematopoietic malignancies,
median age 39 years (range: 20–64), were enrolled from August
2000 to October 2009 in a single center, non-randomized prospec-
tive phase I–II clinical trial (ALT-TEN protocol) approved by the
San Raffaele Scientific Institute’s Ethics Committee and the Italian
Ministry of Health. The clinical trial was registered in the public
cell therapy national database of the Italian Istituto Superiore di
Sanità (registration number IS/11/6172/8309/8391). All patients
signed informed consent. Enrolled patients were candidates for
haplo-HSCT from family donors, since they did not have a timely,
suitable HLA-matched family or unrelated donor. Full haplotype
mismatching was defined as ≥2 HLA-A, HLA-B, or DRB1 anti-
gen disparity. At the time of trial design, information from the
literature and our clinical experience clearly indicated that over-
all probability of survival after TCD haplo-HSCT was very poor
(1). Therefore, the approval for the ALT-TEN trial, as a proof-of-
concept study, was given for a small cohort of patients, and the San
Raffaele Scientific Institute’s Ethics Committee agreed on a single-
arm study design (see Table 1 for overall patients’ characteristics,
treatment, and outcome). Patients received myeloablative con-
ditioning and standard infection prophylaxis with voriconazole,
levofloxacine, or acyclovir, followed by infusion of highly puri-
fied granulocyte-colony-stimulating (G-CSF)-mobilized CD34+
donor cells, selected with the CliniMACS one-step GMP-validated
procedure (CliniMACS, Miltenyi Biotec, Bergisch-Gladbach, Ger-
many), containing approximately 104 CD3+/kg donor-derived T
cells. Time to myeloid engraftment was defined as the first of
three consecutive days of neutrophil counts ≥500/µl and platelet
counts ≥25000/µl. Complete chimerism was defined as ≥95%
of donor cells in the bone marrow. The distribution of patients
enrolled in the trial is reported in Figure 1. Two (patients 8
and 17) of the 19 patients enrolled in the proof-of-concept ALT-
TEN clinical trial were not transplanted because of relapse in
the pre-conditioning phase and donor screening failure, respec-
tively, thus they were excluded from the study because they did
not undergo haplo-HSCT. Transplanted patients (n= 17) received
a median of 12× 106 CD34+ cells/kg (range, 3.8–19.2), and
1× 104 CD3+ T cells/kg (range, 0.4–2.6). All but two trans-
planted patients (patients 12 and 19, in whom primary graft
failed), achieved myeloid engraftment. Median time to an absolute
neutrophil count of 500/µl and to a platelet count >25000/µl
was 15 days (range, 10–23 and 10–26, respectively; patient 2 never
reached a platelet count >25000/µl). IL-10-DLI were successfully
good-manufacturing-practice (GMP)-produced in 14/17 patients
(patients 10, 13, and 19: level of anergy <67%). Among these 14
patients, 2 could not be treated with IL-10-DLI because of graft
failure (patient 12), or because they did not meet the eligibil-
ity criterion for early autologous reconstitution (patient 15 and
patient 13, who also had no anergy). Therefore, five of the trans-
planted patients did not receive IL-10-DLI. Among them, two died
because of infections (patients 10 and 12 at day 169 and 32 post-
HSCT, respectively), two had disease recurrence (patients 13 and
15), and one (patient 19) received a second transplant from the
same haploidentical donor because of graft failure.
IL-10-ANERGIZED T-CELL PRODUCTION AND PROTOCOL OF INFUSION
PBMC were collected by leukapheresis from the donors before
G-CSF mobilization, and from the patients before the condition-
ing regimen. Cell manipulation was performed in GMP-validated
conditions and cell product manufacture was approved by the
Italian Ministry of Health. The method of cell production and
the characterization of the cell product have been described in
detail (25, 29). The donor-derived cell product was obtained after
a mixed lymphocyte reaction (MLR) toward host-derived cells,
in the presence of IL-10 (clinical-grade provided by Schering-
Plough), for 10 days (MLR/10) (25). Host-derived stimulator cells
were CD3-depleted PBMC. The cell product acquired host-specific
hypo-responsiveness, called “anergy” and calculated as follows:
[MLR – MLR/10 : MLR]× 100. Data obtained in preclinical stud-
ies showed that IL-10-anergized cells do not change their phe-
notype as compared to the unmanipulated donor PBMC, do
express very low activation markers such as CD25 and HLA-DR,
are anergic toward the host alloAgs in proliferation and have a
decreased frequency of (antigen specific) cytotoxic CD8+ T cell
precursors.
Percentages of anergy (≥67%, calculated as above and based on
mean values −2 SD of percentage of anergy obtained from more
than 30 donor pairs during the process of development) and cell
viability (≥70%) were chosen as release criteria because consid-
ered to be essential for safety and efficacy of the infused cells. Cell
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Bacchetta et al. Tr1 cell therapy after allogeneic HSCT
Table 1 | Outcome of the IL-10-DLI treated patients.
Pt No. Sex/
age
Disease (status at
haplo-HSCT)
Myeloid
engraftment
IR aGvHD
(grade)
GvHD treatment
duration (months)
Outcome
(cause)
Overall
survival
PMN PLTs
Days from
haplo-HSCT
Days from
IL-10-DLI
Days from
haplo-HSCT
1 M/21 HD (Advanced) 18 18 no no – Death (infection) 43
2 F/59 sAML (Advanced) 13 ? no no – Death (relapse) 72
3 M/31 NHL (Advanced) 17 26 no no – Death (infection) 97
4 M/39 ALL (Advanced) 10 10 no no – Death (relapse) 35
5 F/36 AML (CR3) 11 11 18 24 (III) 11 Death (infection) 355
6 M/58 NHL (Advanced) 23 24 15 47(II/III) 39 Alive/IR 3017
7 M/64 AML (PIF) 13 15 28 34 (II) 4 Alive/IR 2653
9 M/20 HD (Advanced) 19 18 102 99 (II) 10 Alive/IR 2441
11 F/22 AML (CR2) 17 14 33 74 (II) 1.5 Alive/IR 2339
14 M/29 HD (Advanced) 12 20 no no – Death (infection) 69
16 F/25 HD (Advanced) 22 22 no no – Death (graft rejection) 44
18 M/39 AML (CR1) 17 17 no no – Death (graft rejection) 43
Pt No., patient number of enrollment. M, male; F, female diseases: HD, Hodgkin’s disease; sAML, secondary acute myeloid leukemia; NHL, non-Hodgkin lymphoma;
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MDS, myelodisplastic syndrome; Haplo-HSCT, hematopoietic stem cell transplantation from
haploidentical donors. As “advanced status of diseases” are considered lymphoprolipherative disorders in partial remission or with progressive disease and acute
leukemia not in remission. CR, complete remission (CR1 first, CR2 second, CR3 third); PIF, primary induction failure; PMN, polymorphonucleated cells; PLTs, platelets;
IR, Immune reconstitution; CD3+ T cells >100/µl. IL-10-DLI, IL-10-anergized donorT cells. For patient 9, who received 2 IL-10-DLI, timing of immune reconstitution and
acute GvHD onset is calculated from the first IL-10-DLI. aGVHD, acute graft-versus-host-disease.
FIGURE 1 | Patients’ distribution and overall outcome of patients
enrolled in ALT-TEN trial. IL-10-DLI: IL-10-anergized donor T cells; immune
reconstituted patients: CD3+ T cells >100/µl.
viability, phenotype, anergy, and proliferative capacity of each of
the cell preparations infused in the patients showed no significant
variability and are reported in the Table 2.
IL-10-DLI, either fresh or frozen, were administered after sus-
tained neutrophil engraftment and not before 1 month post-HSCT
in order to exclude confounding overlapping events, such as acute
GvHD due to contaminating donor T cells comprised within the
graft and lytic effect of ATG toward the IL-10-DLI. All infusions
were performed in the absence of Immunosuppression (IS). Eligi-
bility criteria for IL-10-DLI were lack of immune reconstitution,
defined by circulating CD4+ T cells ≤50/µl, no signs of GvHD,
and absence of relapse. The protocol was designed for administra-
tion of escalating cell doses every three patients (105, 3× 105 and
106, 3× 106 CD3+ T cells/kg), or of the dose not considered toxic
in at least 10 patients.
The primary endpoints of the cell therapy trial were safety
defined as no acute adverse reactions, no bone marrow aplasia
and lack of GvHD> grade II unresponsive to treatment. Sec-
ondary endpoints were immune reconstitution, defined as periph-
eral CD3+ T cells >100/µl (value based on the time of effective
immune reconstitution reported in previous trials of adoptive
transfer performed at our Institute) (10), number of infectious
episodes and restored in vitro immunological functions.
IMMUNOLOGICAL STUDIES
Routine tests, required during follow-up after haplo-HSCT, were
performed at the HSR diagnostic laboratories (Laboraf), and
included complete hematological evaluation, immunophenotyp-
ing (CD3, CD4, CD8, CD16, CD56, and CD19), monitoring
of blood or tissue CMV and Epstein-Barr viral loads. Further-
more, immunophenotype analyses for surface detection of CD25
www.frontiersin.org January 2014 | Volume 5 | Article 16 | 3
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Table 2 | Immunophenotype and function of IL-10-DLI infused in
patients of the ALT-TEN trial.
Markers Treated
(n=12)
IR
(n=5)
Non-IR
(n=7)
mean SD mean SD mean SD
Immunophenotype (% of positive cells in the lymphocyte gate)
CD2 78.6 12.4 79.4 4.0 77.9 17.1
CD3 74.0 13.2 76.8 7.3 71.7 17.0
CD4 55.8 14.7 56.3 11.0 55.4 18.4
CD8 32.6 13.0 33.0 9.4 32.2 16.3
CD14 17.4 12.0 23.3 14.6 12.5 7.4
CD56 26.0 13.8 32.7 17.0 20.5 8.5
CD19 18.0 10.8 19.0 11.2 17.2 11.5
Stimulation Treated
(n=12)
IR
(n=5)
Non-IR
(n=7)
mean SD mean SD mean SD
Anergy (%)
Host-APC 76.8 7.7 80.4 9.3 74.1 5.6
Proliferation (%)
PMA/iono 81.3 16.2 88.8 15.6 76.0 15.6
Cell composition and host antigen-specific unresponsiveness in secondary MLR,
named anergy, and polyclonal response (to PMA+ ionomycin, PMA/iono) of IL-10-
DLI prior to infusion. Percentages are calculated as percentage of proliferative
responses of MLR/10 versus MLR cell cultures.
Mean values and standard deviations (SD) for the group of immune reconstituted
(IR) and non-IR patients are reported. All cell products had vitality >80%.
(2A3, BD Biosciences, San Diego, CA, USA), CD45RA (MI100,
Biolegend, San Diego, CA, USA), CD62L (DREG 56, BD Bio-
sciences, San Diego, CA, USA), CD24 (ML5, BD Biosciences, San
Diego, CA, USA), CD38 (HIT2, BD Biosciences, San Diego, CA,
USA), CD49b (AK-7, Biolegend, San Diego, CA, USA), LAG-
3 (FAB2319P, R&D System) and intracytoplasmic detection of
FOXP3 (259D, BioLegend, San Diego, CA, USA), GZ-B (GB11,
Caltag MedSystems, Buckingham, UK), and phycoerythrin (PE)-
labeled anti-IL-10 (JESS-19F1, BD Biosciences, San Diego, CA,
USA) were performed on freshly or frozen isolated PBMC at
HSR-TIGET. Human peripheral blood was obtained from healthy
donors upon informed consent in accordance with local ethical
committee approval (TIGET PERIBLOOD) and with the Helsinki
Declaration. PBMC were isolated by centrifugation over Lympho-
prep Ficoll gradients (Axis-Shield PoC AS, Oslo, Norway). For
FOXP3 detection cells were fixed and permeabilized with FOXP3
Fix/Perm buffer set (Biolegend), stained following the manufac-
turer’s instructions and analyzed by FACS Calibur (BD). The
staining for CD49b and LAG-3 was performed at 37°C for 15 min.
Samples were acquired using a BD FACS Canto flow cytometer
(BD Biosciences), and data were analyzed with FlowJo software.
Quadrant markers were set accordingly to unstained controls.
For in vitro functional assays total PBMC were plated at
105/well in 96-well plates in the presence of viral antigens: HSV-
1 and -2 (2.5µg/ml; Advanced Biotechnologies Inc., Columbia,
USA) or CMV (lysate of infected human fibroblasts; diluted 1:30;
kindly provided by Dr. Chiara Bonini, Laboratory of Experimental
Hematology, HSR, Milan Italy). At day 4, cells were pulsed
overnight with 1µCi/well 3H-thymidine (Perkin Elmer, MA,
USA). In parallel, cells were stimulated with coated anti-CD3
(10µg/ml; OKT3; Ortoclone, Jansen-Cilag, Raritan, NJ, USA)
and soluble anti-CD28 (1µg/ml; BD Pharmingen, San Diego,
CA, USA) mAbs, PHA (1µg/ml; Roche Diagnostics GmbH,
Mannheim, Germany), and IL-2 (50 UI/m; Chiron Italia, Milan,
Italy) for 3 days. After stimulation, cells were pulsed for 16 h with
1µCi/well 3H-thymidine. For IFN-γ ELISPOT analysis, multi-
Screen HTS 96-well plates (Millipore, Billerica, MA, USA) were
coated with captured anti-human IFN-γ mAb (IFNγ ELIspot KIT,
ENELHIFNG, Thermo Scientific, Rockford, IL, USA) (30, 31).
After saturation, thawed PBMC from patients and healthy donors
were added in triplicate wells (3× 105 cells/well) and were incu-
bated for 18 h at 37°C in 5% CO2 in the presence of CMV infected
cell lysate. Stimulation with PMA (10 ng/ml; Sigma, St Louis, MO,
USA) plus Ionomycin (150 ng/ml; Sigma) was used as a positive
control, and cells in medium alone were used as negative control.
After washing, the second biotinylated anti-IFN-γ mAb (Thermo
Scientific) was added, followed by Streptavidin–Alkaline Phos-
phatase conjugate (Roche) and then substrate (AEC Staining Kit,
Sigma). After drying, spots were counted using an Elispot Reader
(A. ELVIS GmbH, Hannover, Germany). The number of CMV-
specific T cells, expressed as spot-forming cells per 1× 106 PBMC,
was calculated after the subtraction of negative control values.
T-CELL REPERTOIRE ANALYSIS
TCR repertoire analysis (TcLandscape) was performed by TcLand
Expression (Nantes, France), following the standardized and val-
idated methods established in RISET [reprograming the immune
system for the establishment of tolerance (RISET)1]. PBMC from
patients’ blood, collected in EDTA tubes, were isolated by cen-
trifugation over Lymphoprep Ficoll gradient (Axis-Shield) and
frozen in EUROzol® reagent (Euroclone Spa Life Sciences Divi-
sion, Milan, Italy) for RNA extraction. Total RNA was reverse-
transcribed using an Invitrogen-Life Technologies cDNA synthesis
kit (Roche Diagnostics). Complementary DNA was amplified by
PCR using couples of primers specific for each Vβ genes (32). The
amplification products were then elongated and electrophorized
on a capillary sequencer (Applied Biosystems – Life Technolo-
gies 3730) to separate them according to their length (33). The
complementarity-determining-region-3 (CDR3) profiles or spec-
tra types obtained were transformed into mathematical distribu-
tions. In parallel, the level of Vβ family transcripts was measured
by real-time quantitative PCR and normalized by a housekeeping
gene (HPRT). Each CDR3 length distribution was then multiplied
by the corresponding normalized Vβ transcript amounts and com-
bined within the TcLandscape® representation (34). To explore the
evolution of the TCR repertoire of a patient, we used the Principal
Component Analysis (PCA) on the percentage of the Vβ family
transcripts. This multivariant exploratory statistical technique is
used to simplify complex data sets and to provide a “projection”
of the data into a reduced, easily visualized space. In our context,
1www.risetfp6.org
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PCA allowed us to project the different time-points of each patient
in a factorial space defined by axes, named components (C), which
are linear combination of optimally weighted observed variables.
The PAST software (Palstat: Statistics for Paleontologists and Pale-
obiologists. JS Whalley, PD Ryan 1995) was used for PCA and data
representation.
GENE-EXPRESSION ANALYSIS
Microarray analysis was carried out by Miltenyi Biotec GmbH
(Bergisch-Gladbach, Germany), according to the validated
RISET methods. The data discussed in this publication have
been deposited in NCBI’s Gene-Expression Omnibus (35)
(GSE218852). Peripheral vein blood was drawn directly into PAX-
gene blood RNA tubes (QIAgen, Crawley UK) and extracted
using the PAXgene Blood RNA Kit, which includes DNAse I
treatment (QIAgen). The quality and integrity of RNA were deter-
mined using the Agilent RNA 6000 Nano Kit on the Agilent
2100 Bioanalyzer (Agilent Technologies). RNA was quantified by
measuring A260 nm on an ND-1000 Spectrophotometer (Nan-
oDrop Technologies). 0.5µg total RNA was labeled using the
Agilent Low RNA Input Linear Amp Kit (Agilent Technologies)
as detailed in the “One-color microarray-based gene-expression
analysis protocol”(version 5.5, part number G4140-90040). 0.6µg
Cy3-labeled fragmented cRNA was hybridized on the RISET 1.0
microarray platform according to the “One-color microarray-
based gene-expression analysis protocol” (version 5.5, part num-
ber G4140-90040). The last washing step was performed with
acetonitrile for 30 s. RISET 1.0 is a custom Agilent 8 K× 15 K
60mer oligonucleotide microarray comprising 4,610 probes rep-
resented in triplicates that is dedicated to transplantation research
and was designed based on published and unpublished data pro-
vided by RISET consortium partners. Probe design was optimized
for the detection of multiple transcript variants of a gene, on
optimized hybridization properties of the probes, and avoiding
cross-hybridization. Fluorescence signals of the hybridized Agi-
lent Microarrays were detected using Agilent’s Microarray Scanner
System (Agilent Technologies, Inc.). The Agilent Feature Extrac-
tion Software (FES v. 10.2.1.3/10.5.1.1) was used to read out
and process the microarray image files. To determine differential
gene-expression, FES derived data were further analyzed using the
Rosetta Resolver gene-expression data analysis system (v. 7.2.2.0.0.,
Rosetta Inpharmatics LLC).
For time-course analysis, background-corrected signal inten-
sity values were transformed to base two logarithms and quantile
normalized. The open-source STEM (“Short Time-series Expres-
sion Miner v1.3.4”) software (36) was used with the default
settings and the“No normalization/add 0”option. Expression pro-
files representing microarray probes with an increase or decrease
expression level in the late-time samples (≥1 year after IL-10-
DLI) were selected separately for each patient. An intersection of
probes, identified for each patient, was applied for the generation
of hierarchically clustered heat maps by using the MeV package (v.
4.5.1) (37). The lists of genes, with increased or decreased expres-
sion levels in the late-time samples of patients 7, 9, and 11, were
2http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21885
analyzed for a significant enrichment of biological pathway anno-
tation terms in comparison to the complete RISET 1.0 microarray
configuration. Term-enrichment relative to the expected back-
ground distribution was scored using Fisher’s exact test with
Benjamini-Hochberg correction. Annotations were derived from
different sources, e.g., Gene Ontology (GO3), signaling pathway
membership, sequence motifs, chromosomal proximity, literature
keywords, and cell-specific marker genes. No relevant terms were
returned for the genes downregulated in the late-time samples
(not shown). Gene-expression pattern of 166 time-course sensitive
microarray probes were used for the generation of median inter-
experiment correlation coefficients between patient and healthy
control-derived samples, analyzed according to the time-span after
starting IS and after its discontinuation.
The microarray dataset including patients 7, 9, and 11 generated
on the RISET 1.0 Agilent platform (GEO Series accession num-
ber GSE21885) was merged with the dataset obtained from the
cohort of kidney transplant recipients studied by Indices of Toler-
ance (IOT) consortium (38) using the RISET 2.0 platform (GEO
Series accession number GSE14655), considering only the 4610
reporters present on both platforms. Expression profiles of the
10 most discriminatory biomarkers of tolerance identified by the
IOT study were extracted from the combined quantile normalized,
log2-transformed dataset. From this data, pairwise Pearson corre-
lation coefficients comparing the medians of each IOT patient
(Tol-DF, tolerant drug-free; s-CNI stably immunosuppressed by
calcineurin inhibitors (CNI); s-nCNI, stable under non-CNI; s-
LP, stable under low dose prednisolone; HC, healthy controls) were
calculated with each separate time-point from patients 7, 9, and 11.
RESULTS
LONG-TERM SURVIVAL IN TRANSPLANTED PATIENTS TREATED WITH
IL-10-DLI
In a pilot study, 12 patients affected by high-risk/advanced stage
hematologic malignancies and previously treated with multi-
ple lines of chemotherapy, were transplanted with haplo-HSCT
and received IL-10-DLI after myeloid engraftment (ALT-TEN
trial). IL-10-DLI were infused at a median of 35 days post-HSCT
(range, 28–64), when no spontaneous immune reconstitution was
detectable in the periphery. Cells were infused in the absence of
pharmacological IS. IL-10-DLI cell dose was 105 CD3+ T cells/kg
in all but one patient (patient 5), who received 3× 105 CD3+ T
cells/kg. Four patients (patients 6, 7, 9, and 11), who received IL-
10-DLI at the dose of 105 CD3+ T cells/kg at a median of 40 days
post-HSCT (range, 31–64), survived beyond day 100 post-HSCT
and immune reconstituted (IR) at a median of 28 days post-IL-10-
DLI (range, 15–102 days, Table 1). At present, these four long-term
IR patients are IS-free with an optimal performance status at a
median follow-up of 7.2 years (range 6.4–8.3). All four patients
have a stable full donor chimerism. No disease relapse occurred
in these reconstituted patients, despite the fact that two patients
presented an advanced status of the disease at the time of trans-
plant. Moderate acute GvHD was observed (grade II/III in patient
6 and grade II in patients 7, 9, and 11) starting at a median of
3www.geneontology.org
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60 days (range, 34–99) after IL-10-DLI. Acute GvHD completely
resolved after conventional therapy administered for a relatively
short period in patients 7, 9, and 11 (4, 10, and 1.5 months, respec-
tively), whereas patient 6 required treatment for 39 months, and
responded well to second-line therapy (Table 1).
Overall, IL-10-DLI was efficacious in 4 out of 12 patients, pos-
sibly because these four patients were free of events for a time
period that was sufficient for immune reconstitution to occur.
The remaining eight patients included three patients who died
for infections early post-HSCT (day 43, 69, and 97 in patients 1,
14, and 3, respectively) and four patients who died because of
relapse or lack of engraftment (patient 2, 4, 16, and 18) shortly
after transplant. One patient (patient 5) received a higher dose of
IL-10-DLI (3× 105 CD3+ T cells/kg), which led to rapid immune
reconstitution, but the patient developed severe GvHD unrespon-
sive to treatment and died 1 year post-HSCT because of recurrent
infections related to IS therapy (Figure 1; Table 1).
With the exception of the five IR patients described above, the
overall survival of the patients treated with TCD haplo-HSCT
and IL-10-DLI was comparable to that of patients receiving TCD
haplo-HSCT without DLI. This negative outcome is due to the lack
of immune reconstitution (not-IR) and is in line with that reported
in high-risk patients treated with TCD haplo-HSCT without a
complementary T-cell adoptive immunotherapy (“naked”) (1–3).
None of the patients who failed to achieve immune reconstitution
developed signs of GvHD.
IL-10-DLI cellular products received by the IR or not-IR
patients were comparable in terms of cell composition (propor-
tion of T, B, and NK-cells). Although not statistically different,
the percentages of CD14+ and CD56+ were higher in IR patients
as compared to non-IR patients (23.3± 14.6 vs. 12.5± 7.4% of
CD14+ cells and 32.7± 17 vs. 20.5± 8.5% of CD56+ cells in IR
and non-IR patients, respectively). Overall vitality, degree of host-
specific-unresponsiveness and ability to proliferate in response to
polyclonal stimulation of IL-10-DLI cell products in both IR and
non-IR patients were not statistically significant (Table 2).
IL-10-DLI PROMOTED FAST IMMUNE RECONSTITUTION AFTER TCD
HAPLO-HSCT
It is well established that after TCD haplo-HSCT complete func-
tional restoration of T cells requires 6–9 months in pediatric
recipients, and at least 1 year in adults (4, 5). In the four long-term
surviving IL-10-DLI treated patients (patients 6, 7, 9, and 11),
immune reconstitution occurred at a median of 30 days (range,
15–102) post-IL-10-DLI. At the time of immune reconstitution,
the absolute number of CD3+ T cells was>250/µl (297, 394, 256,
and 925 in patients 6, 7, 9, and 11, respectively), of CD3+CD4+
T cells was >150/µl (176, 163, 157, 294 in patients 6, 7, 9, and
11, respectively) and of CD3+CD8+ T cells was >100/µl (115,
231, 100, 631 in patients 6, 7, 9, and 11, respectively). Figure 2A
shows the kinetics of natural killer (NK)-cell and T-cell recov-
ery in peripheral blood. Peripheral NK cells repopulated shortly
after IL-10-DLI (1–2 weeks). CD3+CD8+ T cells repopulated the
peripheral blood before CD3+CD4+ T cells, leading to a per-
sistent CD4/CD8 inverted ratio. The highest lymphocyte counts
pre-GvHD were 1235, 1291, 500, and 1685 cells/µl, in patients 6, 7,
9, and 11, respectively. CD19+ B-cells were within normal limits
(median, 98/µl; range, 72–251) at a median of 199 days (range,
150–276 days). These data show a faster peripheral lymphocytes
repopulation in IL-10-DLI treated patients as compared to that
reported in the literature for patients post-TCD haplo-HSCT (1).
In these latter patients, NK cell recovery occurred in 2–4 weeks,
whereas T-cell immune reconstitution was delayed, with CD4+
T cells <100 and <200/µl 10 and 16 months after transplanta-
tion, respectively, and B-cell reconstitution required up to 2 years
(6). In IL-10-DLI treated IR patient, peripheral T lymphocytes
had an effector-memory phenotype (CD45RA−CD62−), whereas
naïve T cells (CD45RA+CD62L+) were detected 1 year post-IL-
10-DLI (data not shown). At long-term follow-up, total lym-
phocyte counts were within normal range (2100–3200 cells/µl)
(Figure 2A) with naïve/memory T cell subsets and transitional,
naïve, and memory B-cell subsets all represented (Figures 2B,C).
NORMAL TCR-VBETA REPERTOIRE IN IL-10-DLI TREATED PATIENTS
The evolution of the TcLandscape demonstrated that in long-term
follow-up IR patients, the TCR repertoire progressively became
polyclonal and comparable to that of HC. The expression of the
TCR-Vβ repertoires at different time-points during the follow-up
is represented in Figure 3. Results in one representative patient
(Figure 3A) show that the TCR repertoire in the IL-10-DLI cell
product preinfusion was similar to that of the unmanipulated
donor PBMC. We observed a flat landscape early post-HSCT,
which indicates the absence of T cells. T-cell reconstitution started
with olygoclonal T-cell expansion (red peaks in the landscape),
corresponding to clinical signs of GvHD or infections (Figure 3A).
Later on the TcLandscape gradually became polyclonal (green dis-
tributions) like the donor TcLandscape. The evolution of the TCR
repertoire in the long-term follow-up patients (patients 7, 9, and
11) was also analyzed by PCA on each time-series of TcLandscapes
performed (Figure 3B). PCA produces a map that summarizes the
similarity of TCR-Vβ chain gene-expression considering recipi-
ent cells analyzed at all time-points, donor PBMC and IL-10-DLI
TcLandscapes. It is noteworthy that donor PBMC and IL-10-DLI
are close on the map indicating a similar TCR repertoire. The
itinerary illustrates that the divergence between the donor T-cell
repertoire and the repertoire of donor T cells post-haplo-HSCT
decreases with time. The TCR of the recipient progressively resem-
bles that of the donor, starting from a depleted T-cell landscape to
a fully polyclonal T-cell repertoire.
IMMUNE FUNCTIONS ARE RESTORED IN PATIENTS WITH LONG-TERM
SURVIVAL
In vitro proliferative responses to IL-2 were detectable early post-
IL-10-DLI, consistent with the early reconstitution of NK cells.
Proliferation in response to polyclonal stimuli [anti-CD3/CD28
monoclonal antibodies (mAb) or phytohemagglutinin (PHA)]
and to viral antigens [CMV and Herpes-Simplex virus (HSV)] was
detected between 6 and 12 months post-infusion, after immuno-
suppressive therapy withdrawal (Figure 4A). Interferon (IFN)-γ-
producing CMV- and HSV-specific T cells (Figure 4B) were also
detected by ELISPOT analysis, confirming the presence of viral
reactive T cells in the peripheral blood of long-term IR patients.
It should be noted that in historical controls in vitro T-cell func-
tion was still profoundly impaired 10 months after transplantation
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FIGURE 2 | Immune reconstitution in long-term-surviving IL-10-DLI
patients. (Pt 6, 7, 9, and 11). (A) Kinetics of recovery of peripheral
lymphocyte subsets (absolute number), at different time-points (d, day; y,
year) after infusion of IL-10-anergized donor T cells (IL-10-DLI). For patient
9, who received two subsequent IL-10-DLI, timing is calculated from the
second IL-10-DLI. Reference values for healthy controls (HC) are: total
lymphocytes 1000–4800/µl, CD3+ T cells 781–2664/µl, CD3+CD4+ T cells
397–1762/µl, CD3+CD8+ T cells 224–1762/µl, CD16+CD56+ NK-cells
56–690/µl, CD19+ B cells 57–710/µl. Gray bars indicate the time-frame of
immunosuppression (IS). Infective episodes (febrile episodes of bacterial,
fungal or unknown origin) and viral (cytomegalovirus, Varicella-Zoster
virus, Herpes-Simplex virus, Hepatitis B virus) reactivations detected by
molecular analysis prior to the appearance of clinical manifestations are
indicated (filled and empty diamonds, respectively). (B) Relative
distribution of naïve and memory in gated CD3+ T cells. E, effector T cells
(CD62L−CD45RA+); EM, effector-memory T cells (CD62L−CD45RA−);
CM, central memory T cells (CD62L+CD45RA−); N, naïve
(CD62L+CD45RA+) T cells. HC, n=20. (C) Relative distribution of B-cell
subsets, according to the expression of CD24 and CD38 in gated CD19+
B-cells. T, transitional B cells (CD24brightCD38bright); N, naïve/mature B
cells (CD24dullCD38+); M, memory B cells (CD24brightCD38−). HC,
n=3.
(1–3). Overall, even if in a limited number of patients, immune
reconstitution in IL-10-DLI treated patients was consistently faster
and more efficient in comparison to historical controls, with poly-
clonal and Ag-specific functional responses normalized within the
first year.
Consistently with what observed in vitro, in long-term IR
patients (patients 6, 7, 9, and 11) bacterial and fungal infec-
tions and viral reactivations mainly occurred during pharma-
cological IS (Figure 2A). Overall, in the first 100 days post-
HSCT, the estimated median of infectious episodes was 2.75
episodes/patient in the IL-10-DLI treated long-term IR group of
patients, whereas in the groups of the untreated or IL-10-DLI
treated but non-IR patients, the estimated median of infec-
tious episodes was approximately 4 episodes/patient. Impor-
tantly, no mortality related to infections was observed in the
four IL-10-DLI treated IR patients, whereas the IL-10-DLI
patients who did not achieve immune reconstitution died for
infections and relapse at a median of 72 days from haplo-
HSCT.
IL-10-DLI IMMUNE RECONSTITUTED PATIENTS MAINTAIN
HOST-AG-SPECIFIC UNRESPONSIVENESS AND DISPLAY MARKERS OF
IL-10-MEDIATED TOLERANCE
Donor-derived PBMC isolated from IR patients post-IL-10-DLI
did not proliferate in response to host-antigen-presenting cells
(APCs), in contrast to PBMC collected pre-transplant. However,
these cells displayed normal responses to third party allo-APCs
in vitro (Figure 5A). These results demonstrate the host-specific
unresponsiveness of donor T cells after IL-10-DLI and immune
reconstitution.
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FIGURE 3 |TcLandscape® prior and at different time-points after
IL-10-DLI treatment in haplo-HSC transplanted patients. T cell receptor
(TCR) repertoires of the donor’s PBMC, IL-10-anergized donor T cells
(IL-10-DLI) prior to infusion, and patient’s PBMC before and at different
time-points post-IL-10-DLI, in the presence and absence of GvHD and
immunosuppression (IS). (A) One representative patient (pt 11) out of four
studied is shown. Four-dimensional graphs of the different Vβ families are
shown. X axis, Vβ gene family; y axis, length of the complementarity-
determining-region-3 (CDR3); z axis, amount of Vβ gene normalized by
hypoxanthine-guanine phosphoribosyl transferase; color code, percentage
of perturbation compared to normal Gaussian distribution; d, days; y,
years. (B) TCR repertoire analysis. Evolution of Vβ gene-expression of each
patient by Principal Component Analysis (PCA). PCA allows projection of
the different time-points in a factorial space defined by axes, named
“components,” which are linear combinations of optimally weighted
observed variables. The distance between two time-points is related to
their TcLandscape similarity. For each patient, the percentages of each Vβ
family for all recipient time-points, were independently analyzed by PCA.
The “itinerary” taken by the TCR repertoire of the patient during T-cell
reconstitution is shown by a dashed curve and arrows. Pt: patient;
IL-10-DLI: IL-10-anergized donor T cells infused into the patients; d: days; y:
years.
It is possible that host-specific unresponsiveness is maintained
by the Tr1 cells infused with the IL-10-DLI cell product or by
Treg cells de novo induced during IR. To test this latter hypoth-
esis, we investigated the presence of CD4+CD25+FOXP3+ nat-
ural T regulatory cells (nTregs) and Tr1 cells in IR patients.
Percentages of nTregs were comparable in patients and in HC
(average 5.2 and 4.4% in patients and HC; respectively, not
shown), whereas a low proportion of cells with the Treg-specific
DNA demethylated region (TSDR) of forkhead-box-protein-3
(FOXP3) was detected in patients’ whole blood as compared
to HC [average 0.49% in patients (range: 0.30–0.80%) and
1.4% in HC (range: 0.4–2.9%), in line with what previously
described (39).
A significantly higher percentage of granzyme-B (GZ-B)+IL-
10+ T cells (P = 0.0006) and of CD49b+ Lymphocyte Activation
Gene 3 (LAG-3)+ T cells (P = 0.004) was detected in the PBMC
of IL-10-DLI treated patients compared to HC (Figures 5B,C).
Importantly, cells expressing these biomarkers progressively
increased during follow-up. This observation is consistent with the
high mRNA expression of GZ-B, and LAG-3, between 6 months
and 3 years post-TCD haplo-HSCT in IL-10-DLI treated patients
(not shown).
In each patient, we compared the gene-expression profile
at immune reconstitution, during GvHD and after immune-
suppressive therapy discontinuation to that of three HC recruited
in the “IOT” RISET-EU project (IOT4). Consistently with the
immune-reconstitution, the overall patients’ gene-expression
4http://www.transplant-tolerance.org.uk/
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FIGURE 4 | Immune functions in long-term surviving IL-10-DLI treated
patients. (A) In vitro proliferative responses of PBMC to mitogens and
specific antigens. Data are expressed as counts per minute (cpm) and are
normalized for absolute number of lymphocytes: cpm obtained in response
to addition of exogenous IL-2 are normalized to total lymphocyte counts.
Cpm obtained in response to anti-CD3/CD28 (aCD3/CD28) monoclonal
antibodies and other stimuli, phytohemagglutinin (PHA), and to the viral
antigens Herpes-Simplex virus (HSV) and cytomegalovirus (CMV), are
normalized to the number of CD3+ T cells. Asterisks indicate proliferative
responses of haploidentical donor PBMC before transplant. Pt: patient; d:
days; y: years. (B) Frequency of CMV- and HSV-specific T cells producing
interferon (IFN)-γ in patients’ PBMC. Bars represent the number of IFN-γ
producing T cells specific for CMV, HSV and PMA+ ionomycin (PMA/iono) in
peripheral blood of patients (patients 6, 7, 9, and 11) tested 4, 3.5, 2.7, and
2.5 years after IL-10-DLI, respectively. Healthy controls (HC) were tested in
parallel. Pt: patient.
profiles gradually approximated those of the HC, as visualized
in a hierarchically clustered matrix view of gene-expression
(Figure 6A) and calculated by the inter-experiment correlation
coefficients (>0.9). Of note, in the IL-10-DLI treated patients the
gene-expression profile of the top 10 ranked genes recently iden-
tified as biomarkers of tolerance (38, 40) progressively became
super-imposable to that of kidney transplanted recipients who
did not reject the organ after IS withdrawal. Conversely, the
gene-expression profile of the IL-10-DLI tolerant patients was
different from that of transplanted patients under IS and from
that of HC (Figure 6B). Notably, unlike in HC, in tolerant IL-
10-DLI treated patients and tolerant kidney transplanted recip-
ients, B-cell-related genes were highly expressed [Figure 6B
and (38, 40)].
DISCUSSION
Patients with high-risk/advanced stage hematologic malignancies
who received TCD haplo-HSCT, not followed by any kind of
adoptive immunotherapy (“naked” haplo-HSCT) or followed by
unmanipulated donor T-cell infusions, showed a very high rate of
mortality because of infection and relapse or because of GvHD
(3, 7). In the present study, 12 patients with high-risk/advance
stage hematologic malignancies treated with TCD haplo-HSCT
were infused with donor T cells anergized toward the host allo-
Ags by IL-10. These IL-10-DLI contained both host-specific Tr1
cells and fully competent polyclonal T cells, which could down
modulate host-reactivity and mediate effector responses, respec-
tively (25). Of these 12, 4 patients had a positive outcome after
TCD haplo-HSCT combined with IL-10-DLI, showing fast
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FIGURE 5 | Response to host allo-Ags and biomarkers of tolerance.
(A) Proliferative responses of donor-derived PBMC, toward host-monocytes
before transplantation (pre). Proliferative responses of patient-derived
PBMC (4, 3.5, 2.5, and 2.5 years, post-IL-10-DLI for pt 6, 7, 9, and 11,
respectively) toward host-derived or third-party mature dendritic cells (post).
(B) Intracytoplasmic granzyme-B (GZ-B) and IL-10 on gated CD4+ T cells
from total PBMC of patients 6, 7, 9, and 11, tested 175 days, 2.8, 3, and
5 years; 180 days, 1.5, 2.5, 4, 5, and 7 years; 180 days, 1.5, 2, 2.7, 4.2, 5, and
6 years; 190 days, 1 year, 3.5, 4, 4.2, and 6 years after IL-10-DLI, respectively,
and of healthy controls (HC) (HC: n=10). Mean±SD of the percentage of
IL-10+ T cells of GzB+ T cells and of IL-10+GzB+ T cells in all time-points
analyzed are shown, Differences were evaluated by means of the
non-parametric Mann-Whitney U test. P -values<0.05 were considered
significant. (C) Surface CD49b and LAG-3 on gated CD4+ T cells from total
PBMC of patients 6, 7, 9, and 11, tested 175 days, 2.8, 3, and 5 years;
180 days, 1.5, 2.5, 4, 5, and 7 years; 180 days, 1.5, 2, 2.7, 4.2, 5, and 6 years;
190 days, 1 year, 3.5, 4, 4.2, and 6 years after IL-10-DLI, respectively, and of
HC (HC: n=5), and of donor PBMC of pt 7 and 9 (Donor pre-Tx).
Mean±SD of the percentages of CD49b+LAG-3+ T cells at indicated
time-points are shown. Differences were evaluated by means of the
non-parametric Mann-Whitney U test. P -values<0.05 were considered
significant. cpm: counts per minutes of Tritiated Thymidine incorporation.
immune reconstitution with restoration of normal T naïve and
memory cell subsets, progressive increase in cells positive for
the Tr1 biomarkers and a tolerance signature. These IR tolerant
patients are long survivors, in good performance status and remain
completely disease-free at 7.2 years follow-up (median).
Patients treated with IL-10-DLI who did not immune recon-
stitute displayed post-transplant courses that resemble that of
“naked” transplants. It remains unclear why in these patients
IL-10-DLI infusions were not sufficient to sustain immune recon-
stitution and to prevent infections and relapse. Pre-existing poor
clinical conditions and advanced disease severity at the time of
transplant could account for the lack of positive response to
IL-10-DLI treatment (3, 41).
In the 4 long-term surviving patients, the infusion of IL-10-
anergized T cells shortly after engraftment of the myeloid com-
partment, correlated with an accelerated immune reconstitution
with no relapse, only moderate and transient acute GvHD and no
chronic GvHD. These data strongly support the notion that IL-10-
DLI contributed to the overall success of the treatment. In line with
this conclusion is the observation that once infused, the IL-10-DLI
expanded, as demonstrated by the increase in NK-cells, CD8+, and
CD4+ T cells, and by the progressive restoration of a polyclonal
TCR-Vβ repertoire. However, the infused donor-derived T cells
specific for the host Ags remained unresponsive in vitro. It has to
be defined whether the control of host-reactivity is mediated by Tr1
cells present in the IL-10-DLI infusion, which survived long-term
in vivo, or is due to de novo generated Tr1 cells. Using a combina-
tion of novel Tr1 biomarkers, we showed a progressive expansion
of GZ-B (42, 43)/IL-10 and CD49b/LAG-3 (22) expressing CD4+
T cells in the peripheral blood. Importantly, the percentages of
these cells were significantly higher in the IL-10-DLI long-term
surviving patients [(4, 5, 6) and 6 years after TCD haplo-HSCT for
patient 6, 7, 9, and 11, respectively] compared to healthy subjects.
CD49b and LAG-3 are bonafide biomarkers of Tr1 cells, which
are consistently detected in tolerant patients with stable mixed
chimerism after allogeneic HSCT (22). These data provide evi-
dence of the long-term presence of Tr1 cells in fully immune
competent tolerant patients 5 years after haplo-HSCT and IL-
10-DLI treatment. Expansion of CD4+CD25+FOXP3+ T cells
was not observed at any time in long-term IR IL-10-DLI treated
patients suggesting that nTregs did not have a major role in the
immune reconstitution and in vivo immune modulation (44, 45).
Importantly, after HSCT, the gene-expression profile of IL-
10-DLI treated patients was super-imposable to the tolerance
signature of organ-transplanted patients with tolerant outcomes
after IS withdrawal. Specifically, B-cell-related genes, associated
with operational tolerance in stable kidney transplanted patients
IS-free (38, 40) and in renal transplant recipient treated with reg-
ulatory macrophages (46) were observed in IL-10-DLI treated
patients. This finding supports the hypothesis that IL-10-DLI
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FIGURE 6 | Gene-expression profile analysis of three long-term
follow-up patients. (A) Matrix view of gene-expression data (heat map)
showing genes with significantly increased (violet vertical bar) and decreased
(pink vertical bar) expression levels in samples evaluated at different
time-points post-IL-10-DLI (as indicated in days or years) of patient 7, patient
9, and patient 11 compared to three samples from healthy controls (HC).
Data represent quantiles normalized and median-centered signal intensity
data in log 2 space. Red and green indicate upregulation and downregulation,
respectively, relative to the reporter-wise median. (B) Gene-expression
analysis of the ten most discriminatory biomarkers of tolerance identified
within the Indices of Tolerance (IOT) study in patients 7, 9, and 11. Pairwise
Pearson correlation coefficients comparing the medians of expression in
each IOT patient group (Tol-DF: tolerant drug-free; s-CNI: stably
immunosuppressed by calcineurin inhibitors (CNI); s-nCNI: stable under
non-CNI; s-LP: stable under low dose prednisolone; HC: healthy controls)
with the expression in each separate time-point sample from patients 7, 9,
and 11 are shown. The expression of the most discriminatory IOT biomarkers
in IL-10-DLI treated patients progressively became super-imposable to that in
Tol-DF patients and HC. The gray bars below each graph indicate
immunosuppressive treatment.
treated patients have operational tolerance and provides evidence
that the tolerance signature, once established, can be consistent
across different clinical settings.
Results obtained in 4 haplo-HSCT transplanted patients who
survived long-term after IL-10-DLI are promising especially con-
sidering that 2 of these patients were transplanted during disease
relapse. However, the overall course of the trial highlights a num-
ber of limitations. In the majority of the IL-10-DLI treated patients
relapse or infections occurred prior to or in time proximity with
the infusion, when immunodeficiency was still severe. Therefore,
the selection of patients may not have been optimal to reveal
immune modulating effects of the Tr1 cells comprised in the
IL-10-DLI cell product. In addition, it is possible that IL-10-DLI
should have been administered earlier after transplantation, to
allow parallel myeloid engraftment and immune reconstitution
with better prevention of infections and relapse. Furthermore, the
Tr1 cell frequency in the cell product was rather low as demon-
strated in vitro by IL-10 ELIspot analysis (25). At the lowest
effective dose, IL-10-DLI did not cause adverse effects and only
moderate and transient GvHD. However, a threefold increase in
cell dose provoked GvHD grade III-IV in one patient, suggesting
that the ratio between effector cells and Tr1 cells was too high.
The variability in patient’s outcome was not due to differences
in the anergic state of the infused IL-10-DLI since this parameter
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was very consistent among all treated patients. However, it cannot
be excluded that certain immune genetic characteristics of some
patient/donor pairs, such as the combination of HLA-Ags mis-
matches, rendered them additionally susceptible to post-HSCT
complications. In addition, the phenotype of infused IL-10-DLI
cells was similar in IR patients vs. those who did not, although the
former received an IL-10-DLI infusion that contained a higher,
although not significant, proportion of CD56+ and CD14+ cells.
The higher proportion of CD56+ cells in the IL-10-DLI may have
led to earlier and better protection against infections, and possibly
prevent disease relapse, after infusion, allowing T-cell expansion.
Similarly, the higher proportion of CD14+ cells may reflect a
higher number of APC with tolerogenic properties that could have
favor, once in vivo, Tr1 cell differentiation and tolerance. Therefore,
a possible contribution of NK cells and CD14+ cells in favoring
faster immune reconstitution cannot be ruled out.
Early immune reconstitution post-HSCT has also been
achieved with DLI genetically engineered to express the thymi-
dine kinase suicide-gene (TK-DLI) (10), CD8-depleted DLI (47),
CD25-depleted DLI (48), and CTLA4-Ig-treated BM T cells (49,
50). The incidence of severe GvHD remained high in all but the
TK-DLI clinical trial, in which GvHD was controlled by acy-
clovir treatment, targeting the suicide-gene. Moreover, in these
trials relapse occurred in a relevant proportion of patients (10).
Freshly isolated or in vitro expanded Treg cells (13–15) have been
infused in allo-HSCT or haplo-HSCT recipients to prevent GvHD.
In these studies a reduction, but not abrogation, of GvHD was
observed compared to historical controls. In addition, it should
be noted that Treg cells were detected in the peripheral blood of
treated patients only shortly after infusion (14). A major differ-
ence between the Treg cell trials and the trial with IL-10-DLI is
that, in the former, a pool of polyclonal non-Ag-specific cells was
administered, whereas we used a cell product containing adap-
tive in vitro primed Ag-specific Tr1 cells. A different approach
to administer Ag-specific Tr1 cells has been reported in a cell
therapy trial in patients affected with Chron’s disease. In this
trial OVA-specific IL-10 producing T cell clones were infused and
subsequently re-challenged in vivo by feeding patients, with an
egg-derived peptide. In this study safety and indirect evidences of
clinical benefit were reported but no in vivo tolerance signature
was observed (51).
Overall, the small proof-of-concept clinical trial described here
demonstrates the feasibility of cell therapy with host-specific Tr1
cells and shows promising, although preliminary and uncon-
trolled, efficacy in 4 patients. Future phase I/II trials with larger
cohorts of transplanted patients, homogeneous in terms of dis-
ease and treatment, are required to further prove the efficacy
of this treatment. The present study opens the possibility of
using Tr1 cells as adjuvant treatment also in organ transplanta-
tion, as planned for renal transplant recipient (The ONE study,
European Union Funded Multinational Clinical Trial), and in
other immune-mediated disorders, including inflammatory bowel
diseases and type 1 diabetes.
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